Cellbox Solutions, a Cologne-based warm-chain logistics know-how firm enabling the worldwide transport of residing cells beneath managed physiological circumstances, has raised €3.5 million in a Collection A financing – which stays open for different tranches till Might 2026.
The spherical is led by the digital enterprise angel community Companisto, along with current buyers, together with NRW.BANK. The brand new capital will probably be used to develop worldwide manufacturing and gross sales actions and to unlock further utility areas, notably in cell and gene remedy in addition to in vitro fertilization (IVF).
“Our imaginative and prescient is to redefine how residing cells are transported globally. With the continued assist of our buyers and the strengthening of our management crew with a extremely skilled govt, we’re constructing the inspiration for long-term worldwide progress and increasing the attain of warm-chain logistics throughout medical and analysis functions. We’re satisfied that dependable live-cell transport will turn into a vital part of the worldwide life sciences worth chain,” says Prof Dr Kathrin Adlkofer, Founder and CEO of Cellbox.
Current EU-Startups protection reveals continued funding throughout the European ecosystem supporting cell-based therapies, superior biomanufacturing, and enabling life sciences applied sciences.
For instance, UK startup Tozaro secured €6.9 million to develop partnerships and additional develop its Good Polymer platform designed to cut back the price of cell and gene remedy manufacturing. Within the Netherlands, QT Sense raised €4 million to advance a quantum sensing platform that enables researchers to observe mobile stress in actual time, supporting biomedical and drug growth analysis.
In the meantime, Sweden’s Cellcolabs secured €10.3 million to scale manufacturing capability for stem cell therapies and develop world commercialisation efforts, whereas Finland-based StemSight raised €2.3 million to advance stem-cell-based therapies for extreme blindness in the direction of medical growth. In France, biotech firm baCta secured €7 million to scale its platform utilizing programmable microorganisms as molecular factories for industrial and life sciences functions.
Taken collectively, these rounds characterize over €33 million in disclosed funding throughout adjoining life sciences and biotechnology sectors in 2025–2026.
Inside this broader panorama, Cellbox Options operates in a complementary section of the worth chain, specializing in the logistics infrastructure required for transporting residing cells beneath physiological circumstances – an space anticipated to turn into more and more necessary as cell and gene therapies transfer towards larger-scale medical and business deployment.
“Cellbox addresses a structural hole within the life sciences worth chain: the dependable transport of residing cells at physiological circumstances. As superior therapies scale globally, logistics turns into a important success issue. We view Cellbox not as an incremental product innovation, however as a scalable platform with the potential to redefine how delicate organic supplies are transported throughout analysis and medical environments,” provides Dr Robin Ghosh, Funding Supervisor at Companisto.
Based in 2017, Cellbox Options is a warm-chain logistics know-how firm offering modern options for the worldwide healthcare and life sciences industries to move delicate organic supplies and therapeutics that can not be frozen and require managed physiological circumstances.
The corporate’s moveable CO₂ incubator platform, Cellbox, creates a regulated setting for the transport of residing cells, organoids, tissues, and different superior organic supplies. Temperature and CO₂ ranges are individually adjustable to make sure reproducible incubation circumstances all through cargo.
Its warm-chain know-how permits constantly managed cargo circumstances for as much as 48 hours, preserving cell viability and performance throughout transport.
A key element of this subsequent progress part is the appointment of Dr Bernd Muehlenweg as CBO and CFO of Cellbox.
“Cellbox is setting a brand new benchmark within the transportation of residing cells. By enabling secure, managed, and reproducible transport beneath physiological circumstances, we handle a important bottleneck within the life sciences business. The funding spherical marks an necessary milestone in increasing our worldwide footprint and establishing Cellbox as a worldwide infrastructure normal for residing cell cargo and warm-chain logistics.
“Our patented platform and robust regulatory positioning present a wonderful basis for world scale-up throughout a number of life sciences functions, together with the quickly rising discipline of cell and gene therapies. I stay up for additional strengthening our business operations, increasing our service portfolio, and constructing the organisational constructions required to assist the subsequent part of worldwide progress,” says Dr Bernd Muehlenweg, CBO and CFO of Cellbox Options GmbH.
In the long run, Cellbox goals to ascertain warm-chain logistics as the popular world strategy for transporting residing cells, cell therapies, and delicate organic supplies, additional advancing reliability and reproducibility throughout the life sciences sector.
